View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Uncategorized
May 15, 2020

Rhythm’s setmelanotide for rare obesity conditions will have multiple market access schemes

By Victoria Smith

Rhythm Pharmaceuticals’ drug setmelanotide, indicated for rare obesity disorders, may have to endure risk-sharing, population discounts and value-based agreements with payers for adoption although pharmaceutical mortgages could be a viable alternative. While private insurers and Medicare likely won’t budge on drug access, the rare nature of the disease and consequent high cost makes that doubtful.  

Multiple pricing agreements are driven by the irregularity of the conditions for which setmelanotide is striving for approval, as well as the demanded orphan drug price point of USD 300,000 per year. Read more here.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena